New laboratory analysis found widespread use of neotame, a potent artificial sweetener, in most disposable e-cigarettes sold in the United States, including nicotine-free and nicotine-analogue products.
A phase 3 randomized clinical trial found that cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, improved smoking cessation rates compared with placebo, with higher abstinence rates and reduced craving over 24 weeks.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.